Welcome to our dedicated page for Natera news (Ticker: NTRA), a resource for investors and traders seeking the latest updates and insights on Natera stock.
Natera, Inc. develops and commercializes cell-free DNA and genetic testing for oncology, women’s health and organ health. Company updates commonly cover financial results, revenue trends, laboratory operations and publications supporting tests such as Signatera, Prospera, Panorama and Horizon.
Recurring news also includes oncology molecular residual disease applications, clinical evidence presented at medical meetings, transplant rejection surveillance data, collaborations using Natera assays in drug trials, and patent or litigation developments tied to its MRD technology. The company reports through CLIA-certified and CAP-accredited laboratory operations and through Foresight Diagnostics, its subsidiary.
Natera (NASDAQ: NTRA) reported results from a prospective, multicenter Merkel cell carcinoma (MCC) study published in JAMA Dermatology, showing its Signatera™ minimal residual disease (MRD) test outperformed the Merkel cell polyomavirus antibody test (AMERK) for recurrence prediction and monitoring.
In 169 MCC patients, Signatera showed higher sensitivity (90% vs 55%), stronger recurrence prediction (hazard ratio difference 6.6; p < 0.001), and higher positive and negative predictive values than AMERK. Among patients where both tests detected recurrence, Signatera identified relapse earlier, with a median lead time of 5.1 months vs 2.1 months. According to Natera, Signatera is validated across both virus-positive and virus-negative MCC and retains accuracy after immunotherapy, supporting its role as a universal biomarker for surveillance.
Natera (NASDAQ: NTRA) reported that the finalized MolDx local coverage determination (LCD L40060) for molecular testing for solid organ allograft rejection significantly expands Medicare coverage for its Prospera transplant surveillance tests. The policy, expected to take effect on August 30, 2026, increases covered surveillance test frequencies across kidney, heart, and lung transplantation.
According to Natera, the LCD now allows up to 6 kidney tests in year 1 and 4 per year in years 2–3, 12 heart tests in year 1 and 4 per year in years 2–3, and 12 lung tests in year 1 and 4 per year in years 2–3. “For-cause” coverage remains unchanged. The final LCD improves on the July 2025 draft, which had proposed lower test frequencies, and follows supportive comments from leading transplant medical societies.
Natera (NASDAQ:NTRA) announced that its personalized MRD test Signatera received EU IVDR Class C certification, one of the strictest regulatory standards for in vitro diagnostics.
The certification covers adjuvant and surveillance use across multiple solid tumors and lymphomas and supports continued EU availability beyond the 2028 IVDD transition deadline. It follows recent FDA and PMDA approvals for Signatera indications in the United States and Japan.
Natera (NASDAQ:NTRA) reported new JAMA Oncology data from 298 patients in the GALAXY trial, showing its Signatera MRD test helped predict overall survival benefit from adjuvant chemotherapy in resected colorectal liver metastases.
MRD-positive patients receiving chemotherapy had improved DFS and OS, while MRD-negative patients showed no observed survival benefit.
Natera (NASDAQ:NTRA) and Aveta Biomics announced a strategic partnership for AVTA 30-01, a global Phase 3 registrational trial of oral immunotherapy APG-157 in locally advanced head and neck squamous cell carcinoma.
Serial Signatera MRD testing will assess molecular response in 826 patients across multiple regions, with enrollment expected to begin in 2H 2026. APG-157 holds FDA Fast Track and Orphan Drug Designations.
Natera (Nasdaq:NTRA) and Eledon (Nasdaq:ELDN) formed a strategic partnership to use Natera’s Prospera kidney transplant assessment test in Eledon’s planned Phase 3 trial of tegoprubart.
Prospera will be the exclusive donor-derived cell-free DNA monitoring assay in a ~600-patient kidney transplant study expected to start in late 2026.
Natera (NASDAQ:NTRA) received PMDA regulatory approval in Japan for its Signatera molecular residual disease (MRD) test in the adjuvant treatment setting for colorectal cancer (CRC). Signatera becomes the first PMDA-approved MRD test in Japan, backed by the 2,240-sample GALAXY trial and JSCO/JSMO guidance. Commercial launch in CRC is expected by the end of 2026, subject to final pricing, via exclusive partner SRL and its nationwide lab network.
Natera (NASDAQ:NTRA) announced that the National Comprehensive Cancer Network has updated its Bladder Cancer Guidelines to include tumor-informed multiplex PCR ctDNA-based MRD testing for muscle-invasive bladder cancer (MIBC).
The update grants a Category 1 recommendation for Signatera-guided adjuvant atezolizumab in MRD-positive patients within one year post-cystectomy and recognizes personalized ctDNA-MRD as a prognostic and predictive biomarker in MIBC. Signatera was the MRD assay used in the Phase 3 IMvigor011 trial, and in May 2026 the FDA approved Signatera CDx as a companion diagnostic for MIBC patients who may benefit from adjuvant immunotherapy.
Natera (NASDAQ:NTRA) will showcase its organ health portfolio at the American Transplant Congress, June 20-24, 2026. The company and collaborators plan 21 presentations, including seven oral talks, emphasizing the Prospera dd-cfDNA test for kidney, heart, lung and multi-organ transplant monitoring.
Featured data include PEDAL and ProActive study analyses linking Prospera levels to graft stability, rejection risk and adverse outcomes.
Natera (NASDAQ:NTRA) and CytoDyn (OTCQB:CYDY) announced a strategic collaboration on June 4, 2026 to support leronlimab development in metastatic colorectal cancer (mCRC).
Natera will use its personalized MRD assay Signatera and a large real-world molecular oncology dataset to analyze ctDNA dynamics in samples from CytoDyn’s CLOVER Phase 2 mCRC study.